title: Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients.
abstract: OBJECTIVE
  Previous studies have been inconsistent results about the effects of statins on serum triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and high sensitivity C-reactive protein (hsCRP) levels. We therefore investigated the effects of pitavastatin on serum lipid profiles and hsCRP levels in patients with type 2 diabetes mellitus.
  
  
  METHODS
  The study population was 65 Japanese type 2 diabetic patients who had been administered 2 mg daily of pitavastatin and completed a 6-month follow-up. Serum lipids and hsCRP were measured before and after treatment for 1, 3, and 6 months.
  
  
  RESULTS
  Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and TG had significantly reduced after 1 month and remained reduced for 6 months, while HDL-C levels had significantly increased after 1 month and remained at the higher level for 6 months. Baseline median levels of hsCRP were 0.49 mg/L and showed a significant reduction to 0.37 mg/L at 6 months' treatment (p<0.001). Six-month changes in hsCRP levels were not associated with those in TC, LDL-C, HDL-C or TG.
  
  
  CONCLUSIONS
  Pitavastatin improved serum lipid profiles and reduced serum hsCRP levels in type 2 diabetic patients with relatively low inflammation. The effect on hsCRP was not related to the effects on serum lipid profiles.
authors.affiliation: Department of Medicine, NTT West Osaka Hospital, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Motomura
authors.forename: Maki
authors.initials: M
authors.lastname: Okamoto
authors.forename: Tetsuhiro
authors.initials: T
authors.lastname: Kitamura
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Michio
authors.initials: M
authors.lastname: Otsuki
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Asanuma
authors.forename: Miki
authors.initials: M
authors.lastname: Takagi
authors.forename: Shogo
authors.initials: S
authors.lastname: Kurebayashi
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Satoru
authors.initials: S
authors.lastname: Sumitani
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Saito
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Kouhara
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Nshii
authors.forename: Makoto
authors.initials: M
authors.lastname: Nakao
authors.forename: Masafumi
authors.initials: M
authors.lastname: Koga
authors.forename: Bunzo
authors.initials: B
authors.lastname: Sato
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Morimoto
authors.forename: Soji
authors.initials: S
authors.lastname: Kasayama
mesh_terms: D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011804:Quinolines / Q000627:therapeutic use*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011804:Quinolines; D002097:C-Reactive Protein; C108475:pitavastatin